Long-term observation of familial hypereosinophilia and its effects
Official title: A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression
Run by National Institutes of Health Clinical Center (CC) · NCT00091871 · Data updated 2026-11-12
This study looks at a hereditary condition called familial hypereosinophilia to see how it affects people over time and to learn more about its causes and markers.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 1 Year to 100 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Bethesda, Maryland) |
| Status | Recruiting |
| Started | June 8, 2005 |
| Registry record updated | October 29, 2026 |
| Trial ID | NCT00091871 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include genetically related individuals aged 1-100 from families previously identified with familial hypereosinophilia.
✕Probably not a fit
Patients without a genetic link to a family with familial hypereosinophilia or those with conditions that pose unacceptable risks will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates familial hypereosinophilia (FE), a hereditary form of hypereosinophilic syndrome, by enrolling approximately 50 individuals from a previously studied family. Participants will undergo yearly clinical evaluations, including medical history, physical examinations, and various tests such as bloodwork and echocardiograms. The study aims to understand the natural history, genetic causes, and disease markers associated with FE, while also collecting biological specimens for further research. Although the study does not focus on treatment, appropriate medical care will be provided for those who need it.
Why it matters
Potential benefit: If successful, this study could lead to better understanding and management of familial hypereosinophilia, potentially improving patient outcomes.
How similar studies have gone: While this study focuses on familial hypereosinophilia, similar studies on hypereosinophilic syndrome have shown promise in understanding the condition's mechanisms.
Who can join: the full rules
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Stated willingness to comply with all study procedures and availability for the duration of the study * Male or female, aged 1-100 years of age * Genetically related member of a previously identified family with FE * Ability of subject to understand and the willingness to sign a written informed consent document. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: * Any condition that the investigator feels put the subject at unacceptable risk for participation in the study * Pregnancy (in family members who do not have eosinophilia)
Where it's running
-
National Institutes of Health Clinical Center
Bethesda, Maryland, United States Recruiting
Study contacts
- Principal investigator: Amy D Klion, M.D. — National Institute of Allergy and Infectious Diseases (NIAID)
- Study coordinator: Thomas W Brown, R.N.
- Email: browntw@mail.nih.gov
- Phone: (301) 402-7823
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding the natural history of hypereosinophilia and hypereosinophilic syndromes
This study looks at how unexplained high eosinophil levels and related syndromes affect patients over time to better understand their symptoms and the factors that might influence their condition.
-
Using dupilumab to help patients with hypereosinophilic syndrome who still have symptoms
This study is testing if adding dupilumab to the treatment of adults with hypereosinophilic syndrome can help reduce their ongoing symptoms.
-
Understanding Eosinophils in Immune Conditions
This study is trying to understand how certain white blood cells called eosinophils behave in people with high eosinophil counts due to immune system diseases.
-
Machine learning to distinguish EGPA from HES
This project will test whether machine learning applied to clinical, lab, and instrument data can help tell EGPA apart from HES and predict how patients respond to treatment.
-
Registry of patients with eosinophilia affecting the respiratory system
This study is gathering information from patients with eosinophilic lung diseases to better understand how their blood eosinophil levels relate to their breathing problems and overall health.
-
European database and biobank for childhood interstitial lung diseases
This study is creating a database and biobank to collect information and samples from children with interstitial lung diseases across Europe to improve their treatment and understanding of these conditions.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.